1Jaffe ES, Harris NL, Stein H, et al. World health organization clas- sitication of tumours, pathology and genetics of tumours of haemato- poietic and lymphoid tissues. Lynon: IARC Press. 2001:132 -134.
2Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological defini- tion of Waldenstrom's macroglobulinemia: consensus and panel rec- ommendations from the Second International Workshop on Walden- strom~ Macroglobulinemia. Semin Oneol, 2003 ;30 (2) : 110 - 115.
3Ghobrial IM, Fonseca R, Gertz MA, et al. Prognosticmodel for dis- ease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol,2006;133(2) :158 - 164.
6Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Walden- strom's macroglobulinemia. Blood, 2006 ; 107 (9) :3442 - 3446.
7Lin P, Mansoor A, Bueso-Ramos C,et al. Diffuse large B-cell lym- phoma occurring in patients with lymphoplasmacytic lymphoma/ Waldenstrsm macroglobulinemia. Clinicopathologic features of 12 cases. Am J Clin Pathol, 2003 ;120(2) :246 -253.
8Swerdlow SH, Campo E, Harris NL, et al. World Health Organi- zation Classification of Tumours of Haematopoietie and Lymphoid Tissue [ M ]. 4th ed. Lyon:IARC Press, 2008:194-195.
9Owen RG, Treon SP, A1-Katib A, et al. Clinicopathological definition of Waldenslrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia [J]. Semin Oncol, 2003, 30(2): 110-115.
10Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstr6m' s maeroglobulinemia [J]. N Engl J Med, 2012, 367 ( 9 ) :826-833.
